The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
Status:
Withdrawn
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Single-center, randomized, double-blind, placebo-controlled, proof-of-principle study to
evaluate potential cognitive benefits of a single oral dose of AVL-3288 (3 mg) in the
presence and absence of transdermal nicotine (7 mg/24 hrs) in healthy non-smokers, while
monitoring the safety and tolerability of AVL-3288.
Phase:
Phase 1
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore